Disease mongering in drug promotion: Do governments have a regulatory role?
2006

Disease Mongering in Drug Promotion: Do Governments Have a Regulatory Role?

publication Evidence: moderate

Author Information

Author(s): Barbara Mintzes

Primary Institution: University of British Columbia

Hypothesis

Do governments have a regulatory role in preventing disease mongering in drug promotion?

Conclusion

Regulatory agencies often fail to treat drug promotion regulation as a public health concern, leading to increased disease mongering.

Supporting Evidence

  • Regulatory agencies often lack the resources and authority to effectively oversee drug promotion.
  • Unbranded disease-awareness advertising is becoming more common, leading to potential misinformation.
  • Many countries have limited regulatory frameworks for drug promotion, allowing misleading advertising to persist.
  • Health campaigns must focus on genuine health concerns to be beneficial, but often they do not.

Takeaway

Some companies try to make people think they are sick so they will buy more medicine, and governments need to do a better job of stopping this.

Potential Biases

Potential conflicts of interest among health professionals and regulatory bodies.

Limitations

The article discusses various regulatory failures and does not provide empirical data to support claims.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0030198

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication